The efficacy of azathioprine in relapsing-remitting multiple sclerosis

Neurology. 1991 Jan;41(1):20-5. doi: 10.1212/wnl.41.1.20.

Abstract

We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3.0 mg/kg daily or placebo in a double-masked therapeutic trial. Analysis of data for predetermined primary outcome measures demonstrated a significant difference favoring AZA for observed mean exacerbation rate after 2 years of therapy and time to deterioration in both Ambulation Index and Kurtzke Expanded Disability Status Scale score. This study confirms a modest therapeutic benefit for azathioprine previously reported by other investigators.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Azathioprine / adverse effects
  • Azathioprine / therapeutic use*
  • Disability Evaluation
  • Humans
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / mortality
  • Multiple Sclerosis / physiopathology
  • Recurrence
  • Survival Analysis

Substances

  • Azathioprine